thalidomide has been researched along with Aphthae in 108 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the safety and efficacy of thalidomide for treating esophageal aphthous ulceration in persons infected with human immunodeficiency virus (HIV)." | 9.09 | Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. ( Basgoz, N; Chernoff, M; Fahey, JL; Fox, L; Hooton, TM; Jackson, JB; Jacobson, JM; MacPhail, LA; Sha, BE; Shikuma, CM; Simpson, DM; Spritzler, J; Trapnell, CB; Wohl, DA; Wu, AW, 1999) |
| "An interim analysis of data from a NIAID-supported study determined that thalidomide effectively and safely heals severe mouth ulcers in persons with HIV infection." | 9.08 | Thalidomide effective treatment for AIDS-related mouth ulcers. ( Randall, P, 1995) |
| "Thalidomide was given to 15 patients with severe orogenital ulceration (OGU)." | 9.05 | Thalidomide in severe orogenital ulceration. ( Allen, BR; Jenkins, JS; Littlewood, SM; Maurice, PD; Powell, RJ; Smith, NJ, 1984) |
| "Thalidomide has been advocated as the treatment of choice for recalcitrant aphthae." | 7.69 | Thalidomide-resistant HIV-associated aphthae successfully treated with granulocyte colony-stimulating factor. ( Kostman, JR; Manders, SM; Mendez, L; Russin, VL, 1995) |
| "We report our experience in the treatment of major and minor aphthae with thalidomide." | 7.67 | Treatment of aphthae with thalidomide. ( Agüero, S; Blanco, GF; Grinspan, D, 1989) |
| "During maintenance medication at the fourth and eighth weekend, the two doses (50 and 25 mg/d) of thalidomide were equivalent in reducing the incidence of ulcers, ulcer number, and ulcer pain, respectively (all p > 0." | 5.51 | A Randomized controlled clinical trial on dose optimization of thalidomide in maintenance treatment for recurrent aphthous stomatitis. ( Deng, Y; Du, G; Pan, L; Tang, G; Wang, Y; Wei, W; Yao, H, 2022) |
| "The US FDA-approved thalidomide for the treatment of chronic recurrent/severe erythema nodosum leprosum." | 5.12 | Thalidomide: an experience in therapeutic outcome and adverse reactions. ( Gupta, M; Mahajan, VK; Ranjan, N; Shanker, V; Sharma, NL; Sharma, VC, 2007) |
| "A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the safety and efficacy of thalidomide for treating esophageal aphthous ulceration in persons infected with human immunodeficiency virus (HIV)." | 5.09 | Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. ( Basgoz, N; Chernoff, M; Fahey, JL; Fox, L; Hooton, TM; Jackson, JB; Jacobson, JM; MacPhail, LA; Sha, BE; Shikuma, CM; Simpson, DM; Spritzler, J; Trapnell, CB; Wohl, DA; Wu, AW, 1999) |
| "An interim analysis of data from a NIAID-supported study determined that thalidomide effectively and safely heals severe mouth ulcers in persons with HIV infection." | 5.08 | Thalidomide effective treatment for AIDS-related mouth ulcers. ( Randall, P, 1995) |
| "Thalidomide was given to 15 patients with severe orogenital ulceration (OGU)." | 5.05 | Thalidomide in severe orogenital ulceration. ( Allen, BR; Jenkins, JS; Littlewood, SM; Maurice, PD; Powell, RJ; Smith, NJ, 1984) |
| "English-language articles were identified through a MEDLINE search (1966-February 2001); key terms included thalidomide, child, graft-versus-host disease, cancer, HIV, Crohn's disease, Behçet's disease, and lupus erythematosus." | 4.81 | Thalidomide use in pediatric patients. ( Bessmertny, O; Pham, T, 2002) |
| "Six patients could stop the treatment and further presented minor aphthae, 10 needed minimal daily doses of thalidomide and 7 did not respond to 100 mg daily." | 3.69 | Thalidomide and recurrent aphthous stomatitis: a follow-up study. ( Bedane, C; Bonnetblanc, JM; Royer, C, 1996) |
| "Thalidomide has been advocated as the treatment of choice for recalcitrant aphthae." | 3.69 | Thalidomide-resistant HIV-associated aphthae successfully treated with granulocyte colony-stimulating factor. ( Kostman, JR; Manders, SM; Mendez, L; Russin, VL, 1995) |
| "Thalidomide is being tested as an anti-HIV drug, a weight loss treatment, an immune system regulator, a tuberculosis treatment supplement, and a treatment for microsporidiosis." | 3.69 | Treatment for weight loss, tuberculosis and AIDS? ( , 1995) |
| "Seven patients with prurigo nodularis and one with aphthous stomatitis were given 40-115 g of thalidomide for 1 to 6 years." | 3.67 | Development of polyneuropathy during thalidomide therapy. ( Asboe-Hansen, G; Brodthagen, H; Høyer, H; Wulff, CH, 1985) |
| "Thalidomide alone (200-300 mg daily) or associated with colchicine (2-3 mg daily) was given orally to 25 patients with aphthosis: 8 patients with recurrent oral aphthae; 4 patients with recurrent mucocutaneous aphthosis, without visceral involvement, and 13 patients with Behçet's disease (Touraine's aphthosis)." | 3.67 | [Treatment of aphthosis with thalidomide and with colchicine]. ( Faure, M; Genvo, MF; Thivolet, J, 1984) |
| "We report our experience in the treatment of major and minor aphthae with thalidomide." | 3.67 | Treatment of aphthae with thalidomide. ( Agüero, S; Blanco, GF; Grinspan, D, 1989) |
| "Based on present publications we review indications of the therapy of dermatoses with thalidomide as well as possible mechanisms of action and side effects of this drug." | 3.66 | [Thalidomide in dermatology]. ( Hunziker, T; Krebs, A, 1983) |
| "After 1 month, the increase in the recurrence interval was not shown to differ between the two groups (P = ." | 2.94 | The efficacy and safety of thalidomide on the recurrence interval of continuous recurrent aphthous ulceration: A randomized controlled clinical trial. ( Shi, J; Shi, X; Yang, J; Yang, M; Zeng, Q; Zhao, W; Zhao, X; Zhou, H, 2020) |
| "Colchicine was administered to a total of ten patients, with benefits observed in nine (90%), of whom four showed complete remission." | 2.74 | Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial. ( Hirota, SK; Migliari, DA; Mimura, MA; Sanches, JA; Sugaya, NN, 2009) |
| "Thalidomide in lower intermittent doses is ineffective at preventing recurrence of aphthous ulcers in HIV-infected persons." | 2.70 | Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers. ( Chernoff, M; Fahey, JL; Fox, L; Greenspan, JS; Hooton, TM; Jackson, JB; Jacobson, JM; Pulvirenti, JJ; Shikuma, C; Spritzler, J; Wohl, DA, 2001) |
| "Thalidomide has increasing clinical benefits, including the healing of aphthous ulcers in patients with HIV." | 2.70 | Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group. ( Aweeka, F; Bellibas, SE; Chernoff, M; Jacobson, J; Jayewardene, A; Lizak, P; Spritzler, J; Trapnell, C, 2001) |
| "Thalidomide was first developed and marketed in Germany in the 1950s as a sedative." | 2.68 | Thalidomide: an alternative therapy for treatment of apthous ulcers (canker sores). ( Manesis, DA, 1995) |
| "Thalidomide is an effective treatment for aphthous ulceration of the mouth and oropharynx in patients with HIV infection." | 2.68 | Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. ( Chernoff, M; Fahey, JL; Fox, L; Greenspan, JS; Jackson, JB; Jacobson, JM; Ketter, N; MacPhail, LA; Spritzler, J; Vasquez, GJ; Wohl, DA; Wu, AW, 1997) |
| " We concluded that thalidomide in a dosage of 100 mg/d is an effective treatment of severe aphthous stomatitis but is not without some risk." | 2.67 | Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. ( Bonnetblanc, JM; Claudy, A; Dallac, S; Guillaume, JC; Hans, P; Janier, M; Klene, C; Marchand, C; Revuz, J; Souteyrand, P, 1990) |
| " Data on patient response to treatment and major/minor adverse events were obtained from their clinical and electrophysiologic records." | 2.66 | Thalidomide use in the management of oromucosal disease: A 10-year review of safety and efficacy in 12 patients. ( Harte, MC; Hodgson, TA; Saunsbury, TA, 2020) |
| "Thalidomide is second-line treatment for aphthous stomatitis and chronic graft-versus-host disease in children and has been prescribed for many other conditions including actinic prurigo and epidermolysis bullosa pruriginosa." | 2.52 | Review of thalidomide use in the pediatric population. ( Antaya, RJ; Kim, C; Yang, CS, 2015) |
| "Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects." | 2.43 | Thalidomide: dermatological indications, mechanisms of action and side-effects. ( Hsu, S; Huang, DB; Pang, KR; Tyring, SK; Wu, JJ, 2005) |
| "Recurrent aphthous stomatitis is a common problem with 20% to 50% of the population having experienced simple aphthous lesions (ie, canker sores)." | 2.43 | Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. ( Jorizzo, JL; Letsinger, JA; McCarty, MA, 2005) |
| "Aphthous ulcers are among the most common oral lesions in the general population, with a frequency of up to 25% and three-month recurrence rates as high as 50%." | 2.41 | Treatment strategies for recurrent oral aphthous ulcers. ( Barrons, RW, 2001) |
| "Thalidomide has been used successfully in several other dermatologic disorders, including aphthous stomatitis, Behcet's syndrome, chronic cutaneous systemic lupus erythematosus, and graft-versus-host disease, the apparent shared characteristic of which is immune dysregulation." | 2.41 | Thalidomide: an antineoplastic agent. ( Amato, RJ, 2002) |
| "Apremilast is a phosphodiesterase 4 inhibitor used in psoriasis and psoriatic arthritis Recently, this treatment has received marketing authorization for severe and refractory oral aphthosis in Behçet's disease." | 1.72 | [Interest of Apremilast in idiopathic recurrent aphthous stomatitis: Review of two clinical cases]. ( Delaumenie, S; Fourmond, S; Gourin, MP; Gutierrez, B; Ly, KH, 2022) |
| "Thalidomide regulated gut dysbacteriosis in a species-specific manner and had different sustainable effects on various probiotics and pathogens." | 1.72 | A metagenome-wide association study of the gut microbiota in recurrent aphthous ulcer and regulation by thalidomide. ( Duan, N; Hu, Q; Huang, F; Huang, J; Jiang, H; Lin, L; Liu, Q; Qian, Y; Ruan, H; Song, Y; Wang, W; Wang, X; Xiong, K; Yan, F; Ye, P; Zhao, M; Zheng, L; Zhu, Y, 2022) |
| "Since then, the patient has had two recurrences, coinciding with the reduction of thalidomide dosages, which were controlled by increasing the dose of the immunomodulator." | 1.48 | A Dramatic Case of Odynophagia. ( Diniz-Freitas, M; Diz, P; García-Caballero, L; Limeres, J; Seoane, J; Sopeña, B, 2018) |
| "Thalidomide has reported efficacy in treating refractory idiopathic aphthous ulceration and aphthous ulceration in Behçet disease (BD)." | 1.38 | Refractory aphthous ulceration treated with thalidomide: a report of 10 years' clinical experience. ( Cheng, S; Murphy, R, 2012) |
| "Thalidomide is an effective treatment for recurrent aphthosis but its effectiveness at low dose has been rarely assessed." | 1.36 | [Recurrent aphthosis: safety of low dose thalidomide]. ( Dupond, JL; Gil, H; Hafsaoui, C; Limat, S; Magy-Bertrand, N; Meaux-Ruault, N; Perrin, S, 2010) |
| "Thalidomide was rapidly effective: 85% (78/92) entered complete remission (CR) within a median of 14 days." | 1.36 | Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis. ( Barbarot, S; Bastuji-Garin, S; Chosidow, O; Hello, M; Revuz, J, 2010) |
| "Thalidomide is a drug associated with devastating side effects." | 1.30 | Thalidomide's long and winding road. ( Hanna, L, 1998) |
| "Thalidomide was withdrawn from the market in the early sixties because of major teratogenic effects such as reduction defects of the limbs." | 1.30 | [Thalidomide once more in the spotlight]. ( Cornel, MC; de Jong-van den Berg, LT; Rutgers, J, 1998) |
| "All patients had oral and genital aphthae, and 22 of 25 patients had cutaneous lesions consistent with Behçet's disease." | 1.29 | Behçet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement. ( Jorizzo, JL; Mangelsdorf, HC; White, WL, 1996) |
| "Thalidomide trials have been slow to recruit, therefore buyers clubs are working to make the drug available through their services." | 1.29 | Thalidomide and HIV: several possible uses. ( Smith, D, 1995) |
| "An increasing number of AIDS patients have been noted to suffer severe recurrent aphthous stomatitis (RAS), a condition often associated with high morbidity that remains unresponsive to conventional therapeutic interventions." | 1.28 | Thalidomide: treatment of severe recurrent aphthous stomatitis in patients with AIDS. ( Nicolau, DP; West, TE, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (14.81) | 18.7374 |
| 1990's | 53 (49.07) | 18.2507 |
| 2000's | 19 (17.59) | 29.6817 |
| 2010's | 9 (8.33) | 24.3611 |
| 2020's | 11 (10.19) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, Y | 1 |
| Wei, W | 1 |
| Wang, Y | 1 |
| Pan, L | 1 |
| Du, G | 1 |
| Yao, H | 1 |
| Tang, G | 1 |
| Fourmond, S | 1 |
| Gutierrez, B | 1 |
| Gourin, MP | 1 |
| Delaumenie, S | 1 |
| Ly, KH | 1 |
| Banday, AZ | 1 |
| Joshi, V | 1 |
| Arora, K | 1 |
| Sadanand, R | 1 |
| Basu, S | 1 |
| Pilania, RK | 1 |
| Jindal, AK | 1 |
| Vignesh, P | 1 |
| Gupta, A | 1 |
| Sharma, S | 1 |
| Dhaliwal, M | 1 |
| Rawat, A | 1 |
| Singh, S | 1 |
| Suri, D | 1 |
| Wang, X | 1 |
| Xiong, K | 1 |
| Huang, F | 1 |
| Huang, J | 1 |
| Liu, Q | 1 |
| Duan, N | 1 |
| Ruan, H | 1 |
| Jiang, H | 1 |
| Zhu, Y | 1 |
| Lin, L | 1 |
| Song, Y | 1 |
| Zhao, M | 1 |
| Zheng, L | 1 |
| Ye, P | 1 |
| Qian, Y | 1 |
| Hu, Q | 1 |
| Yan, F | 1 |
| Wang, W | 1 |
| Mahé, E | 1 |
| Zeng, Q | 1 |
| Shi, X | 1 |
| Yang, J | 1 |
| Yang, M | 1 |
| Zhao, W | 1 |
| Zhao, X | 1 |
| Shi, J | 1 |
| Zhou, H | 1 |
| Galán Sánchez, JL | 1 |
| Eguren Michelena, C | 1 |
| de la Cueva Dobao, P | 1 |
| Kolios, AGA | 1 |
| Yawalkar, N | 1 |
| Feusi, A | 1 |
| Kündig, T | 1 |
| Boyman, O | 1 |
| Nilsson, J | 1 |
| Harte, MC | 1 |
| Saunsbury, TA | 1 |
| Hodgson, TA | 1 |
| Arasu, A | 1 |
| Lee, S | 1 |
| Chian Yeoh, A | 1 |
| Ross, G | 1 |
| Soriano, A | 1 |
| Soriano, M | 1 |
| Espinosa, G | 1 |
| Manna, R | 1 |
| Emmi, G | 1 |
| Cantarini, L | 1 |
| Hernández-Rodríguez, J | 1 |
| Sopeña, B | 1 |
| Limeres, J | 1 |
| García-Caballero, L | 1 |
| Diniz-Freitas, M | 1 |
| Seoane, J | 1 |
| Diz, P | 1 |
| Giácaman von der Weth, MM | 1 |
| Tapial, JM | 1 |
| Guillén, BF | 1 |
| Ferrer, DS | 1 |
| Sánchez-Carazo, JL | 1 |
| Ninet, VZ | 1 |
| Saini, A | 1 |
| Ferguson, C | 1 |
| Salkey, K | 1 |
| Kalampokis, I | 1 |
| Rabinovich, CE | 1 |
| Taylor, J | 1 |
| Glenny, AM | 1 |
| Walsh, T | 1 |
| Brocklehurst, P | 1 |
| Riley, P | 1 |
| Gorodkin, R | 1 |
| Pemberton, MN | 1 |
| Yang, CS | 1 |
| Kim, C | 1 |
| Antaya, RJ | 1 |
| Mimura, MA | 1 |
| Hirota, SK | 1 |
| Sugaya, NN | 1 |
| Sanches, JA | 1 |
| Migliari, DA | 1 |
| Gil, H | 1 |
| Perrin, S | 1 |
| Dupond, JL | 1 |
| Meaux-Ruault, N | 1 |
| Hafsaoui, C | 1 |
| Limat, S | 1 |
| Magy-Bertrand, N | 1 |
| Hello, M | 1 |
| Barbarot, S | 1 |
| Bastuji-Garin, S | 1 |
| Revuz, J | 3 |
| Chosidow, O | 1 |
| Cheng, S | 1 |
| Murphy, R | 1 |
| Shetty, K | 1 |
| Ben Slama, L | 1 |
| Sarmadi, M | 2 |
| Ship, JA | 2 |
| Letsinger, JA | 1 |
| McCarty, MA | 1 |
| Jorizzo, JL | 2 |
| Wu, JJ | 1 |
| Huang, DB | 1 |
| Pang, KR | 1 |
| Hsu, S | 1 |
| Tyring, SK | 1 |
| Marque, M | 1 |
| Guillot, B | 1 |
| Bessis, D | 1 |
| Sharma, NL | 1 |
| Sharma, VC | 1 |
| Mahajan, VK | 1 |
| Shanker, V | 1 |
| Ranjan, N | 1 |
| Gupta, M | 1 |
| Grosshans, E | 1 |
| Illy, G | 1 |
| Jenkins, JS | 1 |
| Powell, RJ | 3 |
| Allen, BR | 2 |
| Littlewood, SM | 1 |
| Maurice, PD | 2 |
| Smith, NJ | 2 |
| Bowers, PW | 1 |
| Genvo, MF | 1 |
| Faure, M | 1 |
| Thivolet, J | 1 |
| Torras, H | 2 |
| Lecha, M | 2 |
| Mascaró/, JM | 1 |
| Hunziker, T | 1 |
| Krebs, A | 1 |
| Thompson, C | 1 |
| Gershon, D | 1 |
| Manders, SM | 1 |
| Kostman, JR | 1 |
| Mendez, L | 1 |
| Russin, VL | 1 |
| Laccourreye, O | 1 |
| Fadlallah, JP | 1 |
| Pages, JC | 1 |
| Durand, H | 1 |
| Brasnu, D | 1 |
| Lowenstein, W | 1 |
| Paterson, DL | 1 |
| Georghiou, PR | 1 |
| Allworth, AM | 1 |
| Kemp, RJ | 1 |
| Henriquet, F | 1 |
| Roy, MT | 2 |
| Repetto, T | 2 |
| Fusco, F | 1 |
| Oldfield, EC | 1 |
| Bodokh, I | 1 |
| Lacour, JP | 1 |
| Rainero, C | 1 |
| Castanet, J | 1 |
| Michiels, JF | 1 |
| Ortonne, JP | 1 |
| Menni, S | 1 |
| Imondi, D | 1 |
| Brancaleone, W | 1 |
| Croci, S | 1 |
| Ghigliotti, G | 1 |
| Farris, A | 1 |
| De Marchi, R | 1 |
| Mangelsdorf, HC | 1 |
| White, WL | 1 |
| Solèr, RA | 1 |
| Migliorati, C | 1 |
| van Waes, H | 1 |
| Nadal, D | 1 |
| Weidle, PJ | 1 |
| Harry, TC | 1 |
| Bonnetblanc, JM | 2 |
| Royer, C | 1 |
| Bedane, C | 1 |
| Ball, SC | 1 |
| Sepkowitz, KA | 1 |
| Jacobs, JL | 1 |
| Jacobson, JM | 3 |
| Greenspan, JS | 2 |
| Spritzler, J | 4 |
| Ketter, N | 1 |
| Fahey, JL | 3 |
| Jackson, JB | 3 |
| Fox, L | 3 |
| Chernoff, M | 4 |
| Wu, AW | 2 |
| MacPhail, LA | 2 |
| Vasquez, GJ | 1 |
| Wohl, DA | 3 |
| Bassetti, S | 1 |
| Courvoisier, S | 1 |
| Itin, P | 1 |
| Birnkrant, D | 1 |
| Sharp, M | 1 |
| Getty, J | 1 |
| Klausner, JD | 1 |
| MacPhail, L | 1 |
| Lacosta Nicolás, JL | 1 |
| Martínez Iñiguez, JC | 1 |
| de Jong-van den Berg, LT | 1 |
| Rutgers, J | 1 |
| Cornel, MC | 1 |
| Hooton, TM | 2 |
| Sha, BE | 1 |
| Shikuma, CM | 1 |
| Simpson, DM | 1 |
| Trapnell, CB | 1 |
| Basgoz, N | 1 |
| Gompel, A | 1 |
| Frances, C | 1 |
| Piette, JC | 1 |
| Blanc, AS | 1 |
| Cordoliani, F | 1 |
| Piette, AM | 1 |
| Calabrese, L | 1 |
| Fleischer, AB | 1 |
| Pulvirenti, JJ | 1 |
| Shikuma, C | 1 |
| Barrons, RW | 1 |
| Chavez, EM | 1 |
| Doerr, PA | 1 |
| Henson, BS | 1 |
| Esteve, E | 1 |
| Legac, E | 1 |
| Manesis, DA | 1 |
| Smith, D | 1 |
| Lowell, B | 1 |
| Gilden, D | 1 |
| Baker, R | 1 |
| James, JS | 1 |
| Randall, P | 1 |
| Cooper, S | 1 |
| Hanna, L | 1 |
| Moraes, M | 1 |
| Russo, G | 1 |
| Aweeka, F | 1 |
| Trapnell, C | 1 |
| Jayewardene, A | 1 |
| Bellibas, SE | 1 |
| Lizak, P | 1 |
| Jacobson, J | 1 |
| Taiwo, BO | 1 |
| Amato, RJ | 1 |
| Bessmertny, O | 1 |
| Pham, T | 1 |
| Mascaro, JM | 1 |
| Higgins, SP | 1 |
| Bradbeer, CS | 1 |
| Strazzi, S | 1 |
| Lebbe, C | 1 |
| Geoffray, C | 1 |
| Ablon, G | 1 |
| Morel, P | 1 |
| Verola, O | 1 |
| Molina, JM | 1 |
| Williams, I | 1 |
| Weller, IV | 1 |
| Malni, A | 1 |
| Anderson, J | 1 |
| Waters, MF | 1 |
| Boisnic, S | 1 |
| Tovaru, S | 1 |
| Santis, HR | 1 |
| Allegue, F | 1 |
| Sarriá Cepeda, C | 1 |
| García Rodríguez, M | 1 |
| Tercedor, J | 1 |
| Ortego, N | 1 |
| Ródenas, JM | 1 |
| Hernández, J | 1 |
| Youle, M | 2 |
| Hawkins, D | 2 |
| Gazzard, B | 2 |
| Samson, J | 2 |
| Kuffer, R | 2 |
| Radeff, B | 2 |
| Guillaume, JC | 1 |
| Janier, M | 1 |
| Hans, P | 1 |
| Marchand, C | 1 |
| Souteyrand, P | 1 |
| Claudy, A | 1 |
| Dallac, S | 1 |
| Klene, C | 1 |
| Nicolau, DP | 1 |
| West, TE | 1 |
| Clarbour, J | 1 |
| Farthing, C | 1 |
| Connolly, M | 1 |
| Staughton, R | 1 |
| Grinspan, D | 2 |
| Blanco, GF | 1 |
| Agüero, S | 1 |
| Jenkins, S | 1 |
| Littlewood, S | 1 |
| Wulff, CH | 1 |
| Høyer, H | 1 |
| Asboe-Hansen, G | 1 |
| Brodthagen, H | 2 |
| Eisenbud, L | 1 |
| Horowitz, I | 1 |
| Kay, B | 1 |
| Pinquier, L | 1 |
| Kürkçüoğlu, N | 1 |
| Atakan, N | 1 |
| Eksioğlu, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Topical Rebamipide Versus Topical Betamethasone for Management of Oral Ulcers in Behcet's Disease: A Randomized Clinical Trial[NCT06084624] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Evaluation of a TNF-Alpha Modulator for the Treatment of Oral Lesions in HIV/AIDS Patients[NCT00001524] | Phase 2 | 110 participants | Interventional | 1996-06-30 | Completed | ||
| Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection[NCT00000790] | Phase 2 | 164 participants | Interventional | Completed | |||
| A Randomised, Double-blind, Placebo-controlled Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding[NCT02754960] | Phase 2 | 0 participants (Actual) | Interventional | 2010-03-31 | Withdrawn | ||
| Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation : An Open-label, Randomized, Parallel Controlled Study[NCT00964496] | Phase 2 | 55 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| The Study of the Optimal Treatment Strategy for Patients With Gastrointestinal Bleeding Due to Gastrointestinal Vascular Malformation: a Randomized, Double Blind, Placebo Controlled Study[NCT02301949] | Phase 2 | 0 participants (Actual) | Interventional | 2015-12-31 | Withdrawn | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The cessation of bleeding was defined as repeated negative faecal occult blood test (FOBT) (monoclonal colloidal gold color technology) during our observation period. Rebleeding was defined based on a positive FOBT at any visit after treatment. (NCT00964496)
Timeframe: 52 months
| Intervention | participants (Number) |
|---|---|
| Thalidomide Group | 13 |
| Iron-controlled Group | 0 |
The change from baseline in bleeding duration at 12 months (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | days (Mean) |
|---|---|
| Thalidomide Group | 5.2 |
| Iron-controlled Group | 0.8 |
The Change from baseline in bleeding episodes at 12 months (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | bleeding episodes (Mean) |
|---|---|
| Thalidomide Group | -9.36 |
| Iron-controlled Group | 1.41 |
The change from baseline in average hemoglobin (Hb) level(tested every month) at 12 months. (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | g/L (Mean) |
|---|---|
| Thalidomide Group | 3.06 |
| Iron-controlled Group | -0.01 |
Change of total transfused red cell requirements at 12 months after randomization from one year before baseline in transfusion dependent patients (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | milliliter (Mean) |
|---|---|
| Thalidomide Group | -1585.71 |
| Iron-controlled Group | -28.57 |
Numbers of participants dependent on blood transfusions (NCT00964496)
Timeframe: 52 months
| Intervention | participants (Number) |
|---|---|
| Thalidomide Group | 3 |
| Iron-controlled Group | 13 |
The primary end point was defined as the patients whose rebleeds decreased from baseline by ≥ 50% at 12 months. Reduction of rebleeds = [(total bleeding episode at 12 months - total bleeding episodes at a year before randomization)/total bleeding episodes at a year before randomization(baseline)]*100%. Rebleeding was defined based on a positive fecal occult blood test (FOBT) (monoclonal colloidal gold color technology) at any visit after treatment. (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | participants (Number) |
|---|---|
| Thalidomide Group | 20 |
| Iron-controlled Group | 1 |
20 reviews available for thalidomide and Aphthae
| Article | Year |
|---|---|
Challenges in the diagnosis of periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome in developing countries-A decade of experience from North India.
Topics: Antipyretics; Antiviral Agents; Child; Colchicine; Developing Countries; Fever; Humans; Lymphadeniti | 2022 |
Thalidomide use in the management of oromucosal disease: A 10-year review of safety and efficacy in 12 patients.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Mouth Diseases; Retrospective Studies; Stom | 2020 |
Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide.
Topics: Animals; Autoimmune Diseases; Biological Therapy; Colchicine; Dapsone; Evidence-Based Medicine; Feve | 2020 |
Interventions for the management of oral ulcers in Behçet's disease.
Topics: Acyclovir; Adrenal Cortex Hormones; Alanine; Behcet Syndrome; Colchicine; Cyclosporine; Etanercept; | 2014 |
Review of thalidomide use in the pediatric population.
Topics: Abnormalities, Drug-Induced; Adolescent; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Au | 2015 |
Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide.
Topics: Adult; Algorithms; Behcet Syndrome; Diagnosis, Differential; Female; Humans; Male; Recurrence; Stoma | 2005 |
Thalidomide: dermatological indications, mechanisms of action and side-effects.
Topics: Adult; Behcet Syndrome; Dermatologic Agents; Erythema; Graft vs Host Disease; Histiocytosis, Langerh | 2005 |
Thalidomide therapy for inflammatory dermatoses.
Topics: Abnormalities, Drug-Induced; Adult; Animals; Chemical Phenomena; Chemistry; Female; Humans; Immunity | 1984 |
Sutton's disease (periadenitis mucosa necrotica recurrens).
Topics: Adult; Colchicine; Diagnosis, Differential; Humans; Male; Recurrence; Stomatitis, Aphthous; Thalidom | 1995 |
Thalidomide for aphthous ulcers in patients infected with the human immunodeficiency virus.
Topics: Clinical Trials as Topic; HIV Infections; Humans; Immunosuppressive Agents; Stomatitis, Aphthous; Th | 1996 |
Topical and systemic therapy for recurrent aphthous stomatitis.
Topics: Adjuvants, Immunologic; Administration, Topical; Adrenal Cortex Hormones; Analgesics; Anti-Inflammat | 1997 |
[Treatment of recurrent aphthous stomatitis. A bibliographic review].
Topics: Adrenal Cortex Hormones; Adult; Calcium Phosphates; Dinoprostone; Female; Glycopeptides; Humans; Imm | 1998 |
Thalidomide: current and potential clinical applications.
Topics: Angiogenesis Inhibitors; Anti-HIV Agents; Arthritis, Rheumatoid; Behcet Syndrome; Dermatologic Agent | 2000 |
Treatment strategies for recurrent oral aphthous ulcers.
Topics: Adjuvants, Immunologic; Administration, Topical; Adrenal Cortex Hormones; Aminopyridines; Anti-Infla | 2001 |
Recurrent aphthous stomatitis.
Topics: Administration, Topical; Anti-Inflammatory Agents; Glucocorticoids; Humans; Immunosuppressive Agents | 2000 |
Thalidomide and its dermatologic uses.
Topics: Acquired Immunodeficiency Syndrome; Behcet Syndrome; Dermatologic Agents; Erythema Nodosum; Facial D | 2001 |
Thalidomide: an antineoplastic agent.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; HIV Infections; H | 2002 |
Thalidomide use in pediatric patients.
Topics: Adolescent; Child; Chronic Disease; Female; Graft vs Host Disease; Humans; Hypnotics and Sedatives; | 2002 |
[Evaluation and treatment of aphthous ulcerations of the mouth].
Topics: Anti-Infective Agents, Local; Ascorbic Acid; Behcet Syndrome; Colchicine; Diagnosis, Differential; H | 1991 |
Aphthous stomatitis and its management.
Topics: Adrenal Cortex Hormones; Humans; Stomatitis, Aphthous; Tetracycline; Thalidomide | 1991 |
17 trials available for thalidomide and Aphthae
| Article | Year |
|---|---|
A Randomized controlled clinical trial on dose optimization of thalidomide in maintenance treatment for recurrent aphthous stomatitis.
Topics: Double-Blind Method; Humans; Pain; Recurrence; Stomatitis, Aphthous; Thalidomide | 2022 |
The efficacy and safety of thalidomide on the recurrence interval of continuous recurrent aphthous ulceration: A randomized controlled clinical trial.
Topics: Double-Blind Method; Humans; Quality of Life; Recurrence; Stomatitis, Aphthous; Thalidomide | 2020 |
Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial.
Topics: Adolescent; Adult; Aged; Child; Colchicine; Dapsone; Drug Administration Schedule; Female; Follow-Up | 2009 |
Thalidomide: an experience in therapeutic outcome and adverse reactions.
Topics: Adult; Anti-Inflammatory Agents; Behcet Syndrome; Erythema Nodosum; Female; Humans; Leprosy; Lichen | 2007 |
Thalidomide in severe orogenital ulceration.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Genital Diseases, Fe | 1984 |
Thalidomide effective for AIDS-related oral ulcers.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Esophageal Diseases; Humans; Placebos; Sto | 1995 |
Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection.
Topics: Adult; HIV Infections; HIV-1; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Stomatit | 1995 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antigens, CD; Double-Blind Method; Esophageal Diseases; E | 1999 |
Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers.
Topics: Anti-HIV Agents; Double-Blind Method; HIV Infections; Humans; Immunosuppressive Agents; Recurrence; | 2001 |
Thalidomide effective in treating AIDS-related mouth ulcers.
Topics: Adult; AIDS-Related Opportunistic Infections; Esophageal Diseases; Female; Humans; Immunosuppressive | 1996 |
Thalidomide: an alternative therapy for treatment of apthous ulcers (canker sores).
Topics: CD4 Lymphocyte Count; Double-Blind Method; HIV Infections; Humans; Placebos; Randomized Controlled T | 1995 |
Thalidomide and aphthous ulcers.
Topics: Acquired Immunodeficiency Syndrome; Humans; Placebos; Stomatitis, Aphthous; Thalidomide | 1995 |
Thalidomide for mouth ulcers and wasting.
Topics: Cachexia; Double-Blind Method; HIV Infections; Humans; Placebos; Stomatitis, Aphthous; Thalidomide | 1995 |
Thalidomide effective treatment for AIDS-related mouth ulcers.
Topics: Esophagus; HIV Infections; Humans; Placebos; Stomatitis, Aphthous; Thalidomide; Ulcer | 1995 |
Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Female; HIV Infections; Humans; Male; Middle Aged; Odds Ra | 2001 |
Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Multicenter Studies as Topic; Randomized Controlle | 1990 |
71 other studies available for thalidomide and Aphthae
| Article | Year |
|---|---|
[Interest of Apremilast in idiopathic recurrent aphthous stomatitis: Review of two clinical cases].
Topics: Behcet Syndrome; Humans; Quality of Life; Stomatitis, Aphthous; Thalidomide | 2022 |
A metagenome-wide association study of the gut microbiota in recurrent aphthous ulcer and regulation by thalidomide.
Topics: Dysbiosis; Gastrointestinal Microbiome; Humans; Metagenome; Stomatitis, Aphthous; Thalidomide | 2022 |
Everolimus-induced aphthous stomatitis controlled by apremilast in a heart-transplant patient.
Topics: Antineoplastic Agents; Everolimus; Humans; Stomatitis; Stomatitis, Aphthous; Thalidomide | 2023 |
Apremilast for the treatment of oral aphthae in Behçet disease.
Topics: Administration, Oral; Behcet Syndrome; Humans; Oral Ulcer; Stomatitis, Aphthous; Thalidomide | 2020 |
Apremilast in Treatment-Refractory Recurrent Aphthous Stomatitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Resistance; Female; Humans; Male; Middle | 2019 |
Drug survival of thalidomide for dermatological conditions: A single-centre review.
Topics: Dermatologic Agents; Humans; Prurigo; Skin Diseases; Stomatitis, Aphthous; Thalidomide | 2021 |
A Dramatic Case of Odynophagia.
Topics: Aged; Humans; Immunosuppressive Agents; Male; Pain; Recurrence; Stomatitis, Aphthous; Thalidomide | 2018 |
Complex Aphthae Treated With Apremilast.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Male; Oral Ulcer; Psoriasis; Stomati | 2020 |
Use of Apremilast for Aphthous Ulcers in a Patient With Behçet’s Syndrome
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Behcet Syndrome; Diagnosis, Differential; Drug | 2018 |
Successful management of refractory pediatric-onset complex aphthosis with lenalidomide.
Topics: Adolescent; Diagnosis, Differential; Humans; Immunologic Factors; Lenalidomide; Male; Recurrence; St | 2014 |
[Recurrent aphthosis: safety of low dose thalidomide].
Topics: Adult; Aged; Aged, 80 and over; Behcet Syndrome; Female; Humans; Immunosuppressive Agents; Male; Mid | 2010 |
Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis.
Topics: Adolescent; Adult; Aged; Cohort Studies; Drug Tolerance; Drug-Related Side Effects and Adverse React | 2010 |
Refractory aphthous ulceration treated with thalidomide: a report of 10 years' clinical experience.
Topics: Adolescent; Adult; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Stomatitis, Aphthous | 2012 |
Thalidomide for recurrent aphthous ulcerations.
Topics: AIDS-Related Opportunistic Infections; Humans; Recurrence; Stomatitis, Aphthous; Thalidomide | 2003 |
[Aphthae and aphthosis].
Topics: Anti-Bacterial Agents; Colchicine; Diagnosis, Differential; Humans; Immunosuppressive Agents; Oral U | 2003 |
Refractory major aphthous stomatitis managed with systemic immunosuppressants: a case report.
Topics: Adult; Clinical Protocols; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Patient Educat | 2004 |
Thalidomide for treatment of PFAPA syndrome.
Topics: Adult; Fever; Humans; Immunosuppressive Agents; Lymphadenitis; Male; Periodicity; Pharyngitis; Recur | 2007 |
Effect of thalidomide on orogenital ulceration.
Topics: Adult; Female; Genital Diseases, Female; Genital Diseases, Male; Humans; Male; Recurrence; Stomatiti | 1983 |
[Treatment of aphthosis with thalidomide and with colchicine].
Topics: Adult; Behcet Syndrome; Colchicine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Sk | 1984 |
[Thalidomide in the treatment of aphthosis and Behçet's disease. 4 years' experience].
Topics: Adolescent; Adult; Aged; Behcet Syndrome; Drug Evaluation; Female; Humans; Male; Middle Aged; Necros | 1982 |
[Thalidomide in dermatology].
Topics: Animals; Female; Guinea Pigs; Humans; Immunity; Leprosy; Lupus Erythematosus, Discoid; Male; Mice; N | 1983 |
Finding new uses for thalidomide.
Topics: Acquired Immunodeficiency Syndrome; Anti-Ulcer Agents; Humans; Stomatitis, Aphthous; Thalidomide | 1995 |
Thalidomide-resistant HIV-associated aphthae successfully treated with granulocyte colony-stimulating factor.
Topics: Adult; Granulocyte Colony-Stimulating Factor; HIV Infections; Humans; Stomatitis, Aphthous; Thalidom | 1995 |
Thalidomide in oral aphthous ulceration in patients with HIV infection.
Topics: Adult; Female; HIV Infections; HIV-1; Humans; Male; Stomatitis, Aphthous; Thalidomide | 1994 |
Thalidomide for severe aphthous ulceration in patients with human immunodeficiency virus (HIV) infection.
Topics: Digestive System Diseases; HIV Infections; Humans; Severity of Illness Index; Stomatitis, Aphthous; | 1994 |
[Efficacy of thalidomide against esophageal ulceration in HIV infection].
Topics: Adult; Esophageal and Gastric Varices; HIV Infections; Humans; Male; Stomatitis, Aphthous; Thalidomi | 1993 |
Recurrent giant aphthous ulcers in a child: protracted treatment with thalidomide.
Topics: Child; Humans; Recurrence; Stomatitis, Aphthous; Thalidomide | 1993 |
Thalidomide: treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adult; Female; HIV-1; Humans; Male; Stomatitis, Aphthous; Thalid | 1993 |
New uses of thalidomide.
Topics: Erythema Nodosum; Humans; Stomatitis, Aphthous; Thalidomide | 1996 |
Behçet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Behcet Syndrome; Colchic | 1996 |
Thalidomide treatment of mucosal ulcerations in HIV infection.
Topics: Adolescent; Female; Fissure in Ano; HIV Infections; Humans; Immunosuppressive Agents; Stomatitis, Ap | 1996 |
Thalidomide treatment of mucosal ulcerations in HIV infection.
Topics: HIV Infections; Humans; Leprostatic Agents; Stomatitis, Aphthous; Thalidomide | 1996 |
Thalidomide and recurrent aphthous stomatitis: a follow-up study.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Evaluation Studies as Topic; Female; Humans; Immunosu | 1996 |
Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus: case report and review.
Topics: Adult; Female; HIV Seropositivity; Humans; Stomatitis, Aphthous; Thalidomide | 1997 |
Thalidomide heals HIV-related oral ulcers, but caution is required.
Topics: Acquired Immunodeficiency Syndrome; Humans; Stomatitis, Aphthous; Thalidomide | 1997 |
[Oral ulcers in HIV infection].
Topics: Adult; AIDS-Related Opportunistic Infections; Diagnosis, Differential; Humans; Immunosuppressive Age | 1997 |
Thalidomide for aphthous ulcers in HIV infection.
Topics: HIV Infections; Humans; Stomatitis, Aphthous; Thalidomide; Viral Load | 1997 |
Thalidomide use is associated with weight gain in HIV-1-positive clients.
Topics: Adult; Female; HIV Infections; HIV Wasting Syndrome; HIV-1; Humans; Immunosuppressive Agents; Male; | 1997 |
Thalidomide pros and cons.
Topics: Double-Blind Method; Female; HIV Infections; HIV Wasting Syndrome; Humans; Immunosuppressive Agents; | 1998 |
Thalidomide.
Topics: Abnormalities, Drug-Induced; Adjuvants, Immunologic; AIDS-Related Opportunistic Infections; Anti-Inf | 1998 |
[Thalidomide once more in the spotlight].
Topics: Adult; Bone Marrow Transplantation; Contraindications; Drug and Narcotic Control; Drug Approval; Fem | 1998 |
Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al.
Topics: Adult; Amenorrhea; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Vu | 1999 |
Thalidomide: new preparation. For well-defined indications.
Topics: Behcet Syndrome; Clinical Trials as Topic; Erythema Nodosum; France; Graft vs Host Disease; Humans; | 1998 |
[Discoid lupus, recurrent aphthosis. New indications for thalidomide?].
Topics: Humans; Immunosuppressive Agents; Lupus Erythematosus, Discoid; Recurrence; Stomatitis, Aphthous; Th | 2001 |
[Deep vein thrombosis and pulmonary embolism in a patient with aphtosis treated with thalidomide].
Topics: Adult; Anticoagulants; Humans; Immunosuppressive Agents; International Normalized Ratio; Male; Pulmo | 2001 |
Thalidomide and HIV: several possible uses.
Topics: AIDS-Related Opportunistic Infections; Cachexia; Clinical Trials as Topic; HIV Infections; Humans; N | 1995 |
Growing interest in thalidomide.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cells, Cultured; Clinical Trials as Topic; Female; Humans | 1995 |
Treatment for weight loss, tuberculosis and AIDS?
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Clinical Trials as Topic; Humans; Stomatitis, Aphthous | 1995 |
Thalidomide for wasting syndrome: progress toward compromise.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cachexia; Dose-Response R | 1995 |
Thalidomide, gentrified.
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Drug Costs; Female; Humans; Male; Stomatitis, Aphthous | 1996 |
Thalidomide's long and winding road.
Topics: Abnormalities, Drug-Induced; Clinical Trials as Topic; Drug Approval; Female; Health Services Access | 1998 |
Use of thalidomide in HIV infection.
Topics: Adrenal Cortex Hormones; AIDS-Related Opportunistic Infections; HIV Infections; Humans; Recurrence; | 2001 |
Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis.
Topics: Adult; Behcet Syndrome; Humans; Male; Recurrence; Skin Ulcer; Stomatitis, Aphthous; Thalidomide | 1979 |
Thalidomide: a restricted role.
Topics: Acquired Immunodeficiency Syndrome; Humans; Stomatitis, Aphthous; Thalidomide | 1992 |
Aphthous ulcers in HIV-infected patients: treatment with thalidomide.
Topics: Adult; HIV Infections; Humans; Male; Stomatitis, Aphthous; Thalidomide | 1992 |
Thalidomide hypersensitivity in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Drug Hypersensitivity; Humans; Male; Stomatitis, Aphthous; Thali | 1991 |
[Aphthosis major treated with thalidomide in a patient with AIDS].
Topics: Acquired Immunodeficiency Syndrome; Adult; Humans; Immunosuppressive Agents; Male; Stomatitis, Aphth | 1991 |
[Treatment of recurrent aphthae with thalidomide in patients with acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Adult; Humans; Male; Stomatitis, Aphthous; Thalidomide; Time Fac | 1991 |
Thalidomide in hyperalgic pharyngeal ulceration of AIDS.
Topics: Acquired Immunodeficiency Syndrome; Humans; Hyperalgesia; Hyperesthesia; Pharyngeal Diseases; Stomat | 1990 |
[Thalidomide, the treatment of choice in aphthae in HIV infection].
Topics: HIV Infections; Humans; Stomatitis, Aphthous; Thalidomide | 1990 |
Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: successful treatment with thalidomide.
Topics: Administration, Topical; HIV Infections; Homosexuality; Humans; Male; Middle Aged; Mouth Mucosa; Rec | 1990 |
Thalidomide: treatment of severe recurrent aphthous stomatitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Female; Humans; Male; Recurrence; Stomatitis, Aphthous; T | 1990 |
Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody.
Topics: Adult; Female; HIV Seropositivity; Humans; Male; Recurrence; Stomatitis, Aphthous; Thalidomide | 1989 |
Treatment of aphthae with thalidomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Drug Evaluation; Female; Humans | 1989 |
Thalidomide, orogenital ulcers, and risk of teratogenicity.
Topics: Abnormalities, Drug-Induced; Female; Genital Diseases, Female; Humans; Pregnancy; Risk; Stomatitis, | 1985 |
Development of polyneuropathy during thalidomide therapy.
Topics: Action Potentials; Adult; Aged; Female; Humans; Leg; Male; Middle Aged; Neural Conduction; Neurons, | 1985 |
Recurrent aphthous stomatitis of the Behçet's type: successful treatment with thalidomide.
Topics: Behcet Syndrome; Humans; Male; Middle Aged; Recurrence; Stomatitis, Aphthous; Thalidomide | 1987 |
[Treatment of recurrent buccal aphthosis].
Topics: Colchicine; Humans; Levamisole; Recurrence; Stomatitis, Aphthous; Thalidomide | 1987 |
Significant response of oral aphthosis to thalidomide treatment.
Topics: Adolescent; Adult; Aged; Child; Female; Humans; Male; Middle Aged; Stomatitis, Aphthous; Thalidomide | 1985 |
Thalidomide in the treatment of recurrent necrotic mucocutaneous aphthae.
Topics: Humans; Recurrence; Stomatitis, Aphthous; Thalidomide | 1985 |
Significant response of oral aphthosis to thalidomide treatment.
Topics: Humans; Stomatitis, Aphthous; Thalidomide | 1985 |